Rosuvastatinum + Ezetimibum
Ezehron Duo contains two different active substances in one tablet. One of the active substances is rosuvastatin, which belongs to a group of medicines called statins, and the other active substance is ezetimibe. Ezehron Duo is used to lower the level of total cholesterol, "bad" cholesterol (LDL cholesterol), and a type of fat called triglycerides in the blood, and to increase the level of "good" cholesterol (HDL cholesterol). The medicine works by reducing the amount of cholesterol absorbed in the gut and the amount of cholesterol produced in the body. In most people, high cholesterol does not affect their well-being, as it does not cause any symptoms. However, if left untreated, it can cause fatty deposits to build up in the walls of blood vessels, leading to their narrowing. As a result of the narrowing, it is possible for the blood vessel to become blocked, cutting off blood flow to the heart or brain, leading to a heart attack or stroke. By lowering cholesterol levels, the risk of heart attack, stroke, or other similar health problems can be reduced. Ezehron Duo is used in patients for whom diet alone is not enough to control cholesterol levels. While taking this medicine, the patient should continue to follow a low-cholesterol diet and maintain physical activity. The doctor may prescribe Ezehron Duo if the patient is already taking rosuvastatin and ezetimibe in the same doses as in the combination medicine.
Ezehron Duo does not help with weight loss.
If any of the above situations apply to the patient (or if the patient is unsure), they should consult their doctor.
If any of the above situations apply to the patient (or if the patient is unsure), they should consult their doctor again.
Before taking Ezehron Duo, the patient should discuss it with their doctor or pharmacist if they have kidney problems, liver problems, or have experienced recurring or unexplained muscle pain, or if they or their family members have had muscle diseases or have had muscle problems while taking other cholesterol-lowering medicines. In case of unexplained muscle pain, especially if accompanied by malaise or fever, the patient should immediately consult their doctor. The patient should also inform their doctor or pharmacist about persistent muscle weakness. If the patient is of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean, or Indian), their doctor will determine the appropriate dose of Ezehron Duo. If the patient is taking antiviral medicines, including those used to treat HIV or hepatitis C infection, such as ritonavir with lopinavir and/or atazanavir or simeprevir (see "Ezehron Duo and other medicines"), or if the patient has severe respiratory failure, or if the patient is taking other cholesterol-lowering medicines (fibrates), the patient should read the leaflet carefully, even if they have taken other cholesterol-lowering medicines before. If the patient regularly consumes large amounts of alcohol, or if they have hypothyroidism (underactive thyroid gland), or if they are over 70 years old (as their doctor will need to choose a suitable dose of Ezehron Duo for them), or if they are taking or have taken fusidic acid (an antibiotic) orally or by injection in the last 7 days, the patient should consult their doctor. Taking fusidic acid and Ezehron Duo at the same time can lead to serious muscle problems (rhabdomyolysis). If the patient has or has had myasthenia gravis (a disease that causes general muscle weakness, including muscles involved in breathing) or ocular myasthenia (a disease that causes muscle weakness in the eyes), as statins can sometimes worsen the symptoms of the disease or cause myasthenia. If the patient has ever had a severe skin rash or skin peeling after taking rosuvastatin or other similar medicines.
Ezehron Duo should not be used in children and adolescents under 18 years of age.
The patient should tell their doctor or pharmacist about all medicines they are taking, have recently taken, or might take. The patient should inform their doctor about taking any of the following medicines:
If the patient is to be hospitalized or treated for another illness, they should inform the medical staff that they are taking Ezehron Duo.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine.
Ezehron Duo should not be takenif the patient is pregnant, trying to become pregnant, or thinks they may be pregnant. If the patient becomes pregnant while taking Ezehron Duo, they should stop taking the medicine immediatelyand inform their doctor. While taking Ezehron Duo, women should use effective methods of contraception to avoid becoming pregnant (see "Pregnancy and breastfeeding")
Ezehron Duo should not be takenduring breastfeeding, as it is not known whether the medicine passes into breast milk.
Ezehron Duo is unlikely to affect the patient's ability to drive or use machines. However, the patient should be aware that Ezehron Duo can cause dizziness. In this case, the patient should consult their doctor before driving or using machines.
If the patient has been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is essentially "sodium-free"
This medicine should always be taken exactly as prescribed by the doctor or pharmacist. In case of doubt, the patient should consult their doctor or pharmacist. While taking Ezehron Duo, the patient should continue to follow a low-cholesterol diet and maintain physical activity. The recommended daily dose for adults is one tablet of the prescribed strength.
The medicine can be taken at any time of day, with or without food. The tablets should be swallowed whole, with a glass of water. The patient should take the medicine at the same time every day. Ezehron Duo is not suitable for starting treatment. If treatment is started or the dose needs to be changed, the patient should take each active substance separately and only switch to Ezehron Duo once the doses have been established. The maximum daily dose of rosuvastatin is 40 mg, which is used in patients with high cholesterol levels and a high risk of heart attack or stroke, for whom a dose of 30 mg was not sufficient to lower cholesterol levels.
It is essential to attend regular check-ups with the doctor to ensure that the desired cholesterol level has been achieved and maintained.
In case of overdose, the patient should consult their doctor or the emergency department of the nearest hospital, as medical attention may be necessary.
If the patient misses a dose, they should take the next tablet at the right time. The patient should not take a double dose to make up for the missed dose.
The patient should inform their doctor if they want to stop taking Ezehron Duo. After stopping Ezehron Duo, cholesterol levels may rise again. If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Like all medicines, Ezehron Duo can cause side effects, although not everybody gets them. It is essential for the patient to know what side effects can be associated with taking the medicine. The patient should stop taking Ezehron Duo and seek medical help immediatelyif they experience any of the following:
The patient should consult their doctor immediatelyif they experience any unusual, persistent muscle pain. This condition can rarely progress to life-threatening muscle damage (known as rhabdomyolysis), causing malaise, fever, and kidney problems. To determine the frequency of side effects, the following classification has been used:
headache
constipation
nausea
muscle pain
muscle tenderness
feeling of weakness
dizziness
increased protein in the urine. This symptom usually resolves on its own and does not require stopping Ezehron Duo (applies only to a rosuvastatin dose of 40 mg).
diabetes - this is more likely in patients with high sugar and fat levels in the blood, with overweight and high blood pressure. The doctor will monitor the patient's condition while taking this medicine.
stomach pain
diarrhea
bloating (excess gas in the intestines)
feeling of fatigue
increased results of some blood tests that assess liver function (aminotransferase activity)
rash, itching, hives
increased protein in the urine, which usually resolves on its own, without the need to stop taking Ezehron Duo (applies to rosuvastatin doses of 15 mg and 30 mg)
increased results of certain blood tests that assess muscle condition (creatine kinase activity, CK)
cough
indigestion
heartburn
nausea
joint pain
muscle cramps
neck pain
decreased appetite
pain
chest pain
hot flushes
high blood pressure
tingling
dry mouth
gastritis
back pain
muscle weakness
pain in the arms and legs
swelling, especially of the hands and feet
pancreatitis causing severe abdominal pain, which may radiate to the back
increased tendency to bleed or bruise due to low platelet count.
jaundice (yellowing of the skin and eyes)
liver inflammation
trace amounts of blood in the urine
nerve damage in the legs and arms (e.g., numbness)
memory loss
breast enlargement in men (gynecomastia)
shortness of breath
swelling
sleep disorders, including insomnia and nightmares
sexual disorders
depression
breathing difficulties, including persistent cough and/or shortness of breath or fever
tendon damage
persistent muscle weakness
red, raised rash, sometimes with target-like lesions (erythema multiforme);
muscle tenderness,
gallstones or cholecystitis (which can cause abdominal pain, nausea, vomiting)
myasthenia (a disease that causes general muscle weakness, including muscles involved in breathing)
ocular myasthenia (a disease that causes muscle weakness in the eyes)
The patient should talk to their doctor if they experience weakness in their arms or legs, worsening after periods of activity, double vision, or drooping eyelids, difficulty swallowing, or shortness of breath.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored in its original packaging to protect it from light. There are no special storage temperature requirements. The medicine should be stored out of sight and reach of children. The patient should not take the medicine after the expiry date stated on the carton and blister after EXP. The expiry date refers to the last day of the month. Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.
The active substances of the medicine are rosuvastatin (in the form of rosuvastatin calcium) and ezetimibe. The tablets contain rosuvastatin calcium equivalent to 15 mg, 30 mg, or 40 mg of rosuvastatin. Each tablet contains 10 mg of ezetimibe. The other ingredients are lactose monohydrate, microcrystalline cellulose type 102, sodium croscarmellose, crospovidone type A, povidone K-30, sodium lauryl sulfate, and magnesium stearate.
Ezehron Duo, 15 mg + 10 mg: white or almost white, hexagonal, biconvex, uncoated tablet, approximately 9 x 8 mm in size, with a double-sided engraving "E3". Ezehron Duo, 30 mg + 10 mg tablets: white or almost white, biconvex, uncoated tablet, rectangular in shape, 12 x 6 mm in size, with a double-sided engraving "X". Ezehron Duo, 40 mg + 10 mg tablets: white or almost white, elliptical, biconvex, uncoated tablet, approximately 13 x 6 mm in size, with a double-sided engraving "E6". The packaging contains 28, 30, 56, 60, 90, or 100 tablets in a blister pack of PA/Aluminum/PVC/Aluminum foil, placed in a cardboard box with a patient information leaflet. Not all pack sizes may be marketed.
Adamed Pharma S.A.
Pieńków, ul. M. Adamkiewicza 6A
05-152 Czosnów
tel.: +48 22 732 77 00
Adamed Pharma S.A.
ul. Marszałka J. Piłsudskiego 5
95-200 Pabianice
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.